TrialClinical breast cancer2017

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

José Baselga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.